Previous studies targeting TGFβ1 or TGFβR1 in cardiomyocytes have shown only modest improvements in cardiac fibrosis, with minimal reduction in ventricular dysfunction or myocardial hypertrophy. The gene discussed is TGFB1; the disease is cardiac hypertrophy.